Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Clin Cancer Res. 2018 May 16;24(17):4098–4109. doi: 10.1158/1078-0432.CCR-18-0449

Table 1.

acute GvHD pre-and post-aDLI

Patient aDLI dose level and day Pre-aDLI Post-aDLI
Acute GvHD
Time, Grade (stage)
001 Level 1, D+35 None None
002 Level 1, D+35 None None
003 Level 1, D+35 None None
004 Level 1, D+42 None None
005 Level 2, D+42 D+22 Grade 2 (S2,GI 1, L0) D+98 Grade 2 (S3,GI 0, L1)
010 Level 2, D+34 None None
012 Level 2, D+35 None None
013 None given None N/E
025 None given§ None N/E
026 Level 2, D+35 None D+52 Grade 4 (S0,GI 4, L4)
027 Level 2, D+42 None None
028 || None Given N/E N/E
030 Level 2, D+42 None None
033 Level 2, D+35 None D+54 Grade 1 (S2,GI 0, L0)
035 Level 2, D+35 None None
015 Level 3, D+36 None D+63 Grade 3 (S3,GI 3, L0)
016 Level 3, D+35 None D+62 Grade 3 (S2,GI 3, L0)
018 Level 3, D+35 None None
023 Level 3, D+35 None D+89 Grade 3 (S0,GI 1, L3)

Level 1, 103 CD3 T-cells/Kg, Level 2 104 CD3 T-cells/kg, Level 3, 105 CD3 T-cells/kg; S, skin; GI, gastrointestinal; L, liver

died D+32 of bacterial sepsis prior to infusion of aDLI.

§

Donor not able to donate.

||

non-engraftment followed by autologous reconstitution